Testing lung function decline to time lung transplantation.

1 Amirkhosravi A, Mousa SA, Amaya M, et al. Antimetastatic effect of tinzaparin, a low-molecular-weight heparin. J Thromb Haemost 2003; 1:1972–1976 2 Mousa SA, Mohamed S. Antiangiogenic mechanisms and efficacy of the low molecular weight heparin, tinzaparin: anti-cancer efficacy. Oncol Rep 2004; 12:683–688 3 Von Tempelhoff GF, Harenberg J, Nieman F, et al. Effect of low-molecular weight heparin (certoparin) versus unfractionated heparin on cancer following breast and pelvic cancer surgery: a prospective randomized double-blind trial. Int J Oncol 2000; 16:815–824 4 Altinbas M, Coskun HS, Er O, et al. A randomized clinical trial of combination chemotherapy with and without lowmolecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004; 2:1266–1271 5 Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the Fragmin Advanced Malignancy Outcome Study (FAMOUS). J Clin Oncol 2004; 22:1944–1948